Ondansetron Oral Soluble Pellicles Effectively Reduce the Incidence of Postoperative Nausea and Vomiting Following Primary Total Joint Arthroplasty: A Randomized Controlled Trial.
Yinghao Wang, Shangjie Zhong, Long Zhao et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, controlled, double-masked trial compared preoperative ondansetron oral soluble pellicles (OSP) with placebo for preventing postoperative nausea and vomiting (PONV) after total joint arthroplasty. Among 198 randomized patients, groups received placebo, 8 mg, or 16 mg ondansetron OSP one hour before anesthesia induction. Both active doses reduced PONV incidence compared with placebo; the 16-mg group had lower incidence and nausea severity than the 8-mg group across postoperative time points. Adverse drug reaction rates did not differ markedly. The abstract does not report numerical effect estimates.
Key findings
- Both 8-mg and 16-mg ondansetron OSP reduced PONV incidence compared with placebo after total joint arthroplasty.
- The 16-mg group had lower PONV incidence and nausea severity than the 8-mg group at all postoperative time points.
- Adverse drug reaction rates did not differ markedly among the three groups.
Why it matters
PONV is a relevant postoperative outcome after total joint arthroplasty, and this trial evaluates a needle-free oral delivery option for prophylaxis. The findings support efficacy versus placebo and suggest that 16 mg may provide greater benefit than 8 mg, while reported adverse reaction rates were similar. The abstract provides no numerical effect estimates, so the magnitude of benefit cannot be assessed here.
What to keep in mind
The abstract reports no numerical effect estimates for the outcomes, limiting assessment of the magnitude of benefit.